Rockwell to Discuss Top-Line Results From SFP Phase 3 CRUISE-1; Shares of Inovio Rally After Positive Response Rate from HIV Vaccine Print
By Staff and Wire Reports   
Wednesday, 10 July 2013 19:04
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 10, 2013.

Rockwell Medical (NASDAQ: RMTI)
, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, will host a conference call Wednesday July 10 at 8:00am EDT.  

They will be reviewing  top-line results from their Phase 3 (CRUISE-1) efficacy study of SFP, the Company's late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. Rockwell will announce the top-line results tomorrow morning prior to the call.


======


Inovio Pharmaceuticals, Inc. (NYSE: INO)
announced the peer-reviewed publication of results from two phase I trials (HVTN 070 and HVTN 080) of its PENNVAX^®-B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without Inovio's proprietary CELLECTRA^® electroporation delivery device. The studies were conducted by the HIV Vaccine Trials Network (HVTN). Inovio's HIV DNA vaccine together with the CELLECTRA device significantly increased the number of responders producing robust and durable CD4 and CD8 T-cell responses in humans. The observation of robust T-cell responses against distinct targeted diseases generated by different Inovio SynCon® DNA vaccines delivered using CELLECTRA electroporation technology have now been published in two respected peer-reviewed journals. These results are compelling because T-cells are considered critical to fighting cancers and chronic infectious diseases.

While Inovio previously released preliminary data from these two trials, this comparison and durability data was published in the peer-reviewed Journal of Infectious Diseases in the article, "Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid IL-12 and impact of intramuscular electroporation for delivery." The lead author was Dr. Spyros Kalams, who is Associate Professor of Medicine, Vanderbilt University Medical Center and principal investigator of Vanderbilt's HIV Vaccine Trials Unit for both clinical studies.




Also Wednesday:



CONMED Corporation (NASDAQ: CNMD)
announced today that it expects to report second quarter 2013 financial results before the market opens on Wednesday, July 24, 2013, and will also hold a conference call live over the Internet at 10:00 a.m. Eastern Time that same day.

Cytomedix, Inc. (OTCQX: CMXI)
, a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that the Centers for Medicare and Medicaid Services (CMS) has issued proposed payment regulations under the Physician Fee Schedule (PFS) and the Hospital Outpatient Prospective Payment System (HOPPS) that include proposed guidelines covering Medicare reimbursement for AutoloGel™.

eHealth, Inc. (NASDAQ: EHTH)
, the nation's first and largest private health insurance exchange, announced today that the company plans to release second quarter 2013 financial results on July 25, 2013.

Hansen Medical, Inc. (NASDAQ: HNSN)
, a global leader in intravascular robotics, today announced that it has signed a $33 million, long-term, debt agreement with White Oak Global Advisors, LLC.

Hansen Medical, Inc. (NASDAQ: HNSN)
, a global leader in intravascular robotics, today announced that Will K. Weinstein has been appointed as a Director, effective as of July 8, 2013.

The Agency Inside® Harte-Hanks, a customer engagement agency of Harte-Hanks (NYSE: HHS), announced today that it won two Healthcare Advertising Awards from Healthcare Marketing Report.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)
today announced the appointment of James Geraghty to serve as a member of the Board of Directors and also as its Chairman.

Intuitive Surgical, Inc. (Nasdaq:ISRG)
today reported that equity awards approved by the Compensation Committee of the Board of Directors, which consists entirely of Independent Directors, were made to 48 new employees.

Medistem, Inc. (PINKSHEETS: MEDS)
, today announced a key addition to its executive team with the appointment of John Salvador, J.D. as Chief Operating Officer.

Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK)
today announced its intention to offer, subject to market and other conditions, $50 million of its common stock and $75 million in aggregate principal amount of its convertible senior notes due 2020 (the "Notes") in concurrent underwritten public offerings pursuant to Merrimack's effective Registration Statement on Form S-3 (File No. 333-186369) (the "Registration Statement").

MMRGlobal, Inc. (OTCQB: MMRF)
today announced that following its Annual Meeting of Stockholders scheduled for Wednesday, July 17, 2013, the Company will hold an hour-long Q&A Conference Call, on topics unrelated to the Annual Meeting, hosted by Chief Executive Officer Robert H. Lorsch and Chief Financial Officer Ingrid Safranek for investors.

NuVasive, Inc. (NASDAQ: NUVA)
, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce their participation at the 20th International Meeting on Advanced Spine Techniques (IMAST) from Wednesday, July 10, to Saturday, July 13, 2013, in booth #303 at the Vancouver Convention Center in British Columbia.

Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP)
, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD").

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)
, a developer of oral drug delivery systems, today announced it has entered into definitive agreements with investors to purchase an aggregate of 657,144 shares of common stock at a price of $7.00 per share in a registered direct offering.

Precision Optics Corporation, Inc. (OTCQB: PEYE)
announces that it has joined the Photonics Online business-to-business e-commerce platform, a web community serving the optics and photonics industry since 1997 by providing technical information about the laser, optics, optoelectronics, fiber optics and imaging industries.

PLC Systems Inc. (OTCQB: PLCSF)
, a company focused on innovative medical device technologies, today announced the launch of a featured profile on TheChairmansBlog.com and a new Executive Video featuring President & CEO, Mark R. Tauscher.

The President and CEO of SmartMetric, Inc. (OTCQB: S, MME) Ms. Chaya Hendrick, said that SmartMetric's MedicalKeyring™, that will be released for sale in August next month, has incorporated inside the device the hospital and medical imaging standard called DICOM.

View Systems, Inc. (OTCBB: VSYM)
, a rapidly growing provider of security products for schools, event planners, banks and government institutions, announced today that William M. Pearse has been retained by View Systems to assist with business development, sales and acquisition strategy.

XTL Biopharmaceuticals Ltd. (TASE: XTL), (OTC: XTLBY)
announced today that NASDAQ approved the Company's listing application and its ADRs will be listed for trading on NASDAQ under the ticker symbol "XTLB".



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus